Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
about
A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanomaDNA Methylation and Chromatin Remodeling: The Blueprint of Cancer EpigeneticsModulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectivesRomidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention.Histone deacetylase inhibitors in lymphoma and solid malignancies.Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors.Histone deacetylases and the immunological network: implications in cancer and inflammation.Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma.Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.Epigenetic drug combination induces genome-wide demethylation and altered gene expression in neuro-ectodermal tumor-derived cell lines.
P2860
Q24658533-42360494-22ED-49E5-96C2-1774730816F3Q26749421-06E362F9-EBF4-41E8-99C3-8673DD90F1C7Q30570945-9BD3360D-85B3-444E-874D-7F811B521BE4Q33390876-C0680C21-83C6-4322-9B80-F17A33DC40FCQ34093052-2FB510EF-4687-418C-98F3-1840BE95AF09Q36394885-6C178825-0401-4CB7-BC2B-38C89135E057Q37118947-5EEB6DFC-D362-42AC-A65C-684F97247CF6Q37515346-474DABFE-3DAA-4383-96E7-2ACB544D5785Q37621256-F5A8FECD-F530-4788-B929-128DC236B5DDQ38242979-358077FC-35B0-44DE-988B-4A8C94E5F2C4Q38877252-34C40DD6-4F18-4069-B746-3553C4CB9C8CQ39248784-69666A9C-9EEA-4B34-8C2C-467892B94CBBQ39367196-B664CB92-637B-4A11-8A1F-6909DA5ECE39Q46667078-C691C04D-3818-41CF-ABC6-5D4983EBE05AQ53098086-B6DE2869-CC1A-499C-9C71-5035E065134A
P2860
Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Epigenetic targets in hematolo ...... ACis and demethylating agents.
@en
type
label
Epigenetic targets in hematolo ...... ACis and demethylating agents.
@en
prefLabel
Epigenetic targets in hematolo ...... ACis and demethylating agents.
@en
P2093
P2860
P1476
Epigenetic targets in hematolo ...... ACis and demethylating agents.
@en
P2093
H Miles Prince
Melita Kenealy
Walid Rasheed
P2860
P304
P356
10.1586/14737140.7.10.1439
P577
2007-10-01T00:00:00Z